Juric, Mateja Kralj and Ghimire, Sakhila and Ogonek, Justyna and Weissinger, Eva M. and Holler, Ernst and van Rood, Jon J. and Oudshoorn, Machteld and Dickinson, Anne and Greinix, Hildegard T. (2016) Milestones of Hematopoietic Stem Cell Transplantation - From First Human Studies to Current Developments. FRONTIERS IN IMMUNOLOGY, 7: 470. ISSN 1664-3224
Full text not available from this repository. (Request a copy)Abstract
Since the early beginnings, in the 1950s, hematopoietic stem cell transplantation (HSCT) has become an established curative treatment for an increasing number of patients with life-threatening hematological, oncological, hereditary, and immunological diseases. This has become possible due to worldwide efforts of preclinical and clinical research focusing on issues of transplant immunology, reduction of transplant-associated morbidity, and mortality and efficient malignant disease eradication. The latter has been accomplished by potent graft-versus-leukemia (GvL) effector cells contained in the stem cell graft. Exciting insights into the genetics of the human leukocyte antigen (HLA) system allowed improved donor selection, including HLA-identical related and unrelated donors. Besides bone marrow, other stem cell sources like granulocyte-colony stimulating-mobilized peripheral blood stem cells and cord blood stem cells have been established in clinical routine. Use of reduced-intensity or non-myeloablative conditioning regimens has been associated with a marked reduction of non-hematological toxicities and eventually, non-relapse mortality allowing older patients and individuals with comorbidities to undergo allogeneic HSCT and to benefit from GvL or antitumor effects. Whereas in the early years, malignant disease eradication by high-dose chemotherapy or radiotherapy was the ultimate goal; nowadays, allogeneic HSCT has been recognized as cellular immunotherapy relying prominently on immune mechanisms and to a lesser extent on non-specific direct cellular toxicity. This chapter will summarize the key milestones of HSCT and introduce current developments.
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | BONE-MARROW-TRANSPLANTATION; VERSUS-HOST-DISEASE; CORD-BLOOD TRANSPLANTATION; ACUTE MYELOID-LEUKEMIA; TOTAL-BODY IRRADIATION; KIR LIGAND INCOMPATIBILITY; CHRONIC LYMPHOCYTIC-LEUKEMIA; MINOR HISTOCOMPATIBILITY ANTIGENS; UNRELATED DONOR TRANSPLANTATION; TREATMENT-RELATED MORTALITY; hematopoietic stem cell transplantation; milestones; conditioning; HLA typing; stem cell source |
| Subjects: | 600 Technology > 610 Medical sciences Medicine |
| Divisions: | Medicine > Lehrstuhl für Innere Medizin III (Hämatologie und Internistische Onkologie) |
| Depositing User: | Petra Gürster |
| Date Deposited: | 27 Aug 2020 11:54 |
| Last Modified: | 27 Aug 2020 11:54 |
| URI: | https://pred.uni-regensburg.de/id/eprint/3958 |
Actions (login required)
 |
View Item |
